(Miacalcin®). Data on the bioavailability of Miacalcin® shows great variability with an average bioavailability of 3% as compared to injection (Hinchcliffe et al., 2005). The systemic delivery of calcitonin via the lungs is as a promising alternative (Patton, 2000).
In contrast to other mucosal barriers, the pulmonary epithelium is more permeable to macromolecules and has lower enzymatic activity (Patton, 1996). Yet, certain